BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15027885)

  • 1. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments.
    Melisi D; Troiani T; Damiano V; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2004 Mar; 11(1):51-68. PubMed ID: 15027885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
    Tortora G; Gelardi T; Ciardiello F; Bianco R
    Int J Biol Markers; 2007; 22(1 Suppl 4):S47-52. PubMed ID: 17520581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM; Adjei AA
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras family signaling: therapeutic targeting.
    Cox AD; Der CJ
    Cancer Biol Ther; 2002; 1(6):599-606. PubMed ID: 12642680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular approach to breast cancer treatment.
    Yarden Y; Baselga J; Miles D
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):6-13. PubMed ID: 15490369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targeted agents in the treatment of lung cancer.
    Saba N; Khuri F
    Expert Opin Investig Drugs; 2004 Jun; 13(6):609-29. PubMed ID: 15174948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
    Tortora G; Gelardi T; Ciardiello F; Bianco R
    Int J Biol Markers; 2007 S4 - Jan-Mar; 22(4):47-52. PubMed ID: 28207114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management of advanced non-small cell lung cancer: targeted therapy.
    Isobe T; Herbst RS; Onn A
    Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS inhibitors: potential for cancer therapeutics.
    Kloog Y; Cox AD
    Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Signal transduction inhibitor].
    Ueda Y; Saijo N
    Gan To Kagaku Ryoho; 2001 May; 28(5):591-600. PubMed ID: 11383206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biological design of novel antineoplastic therapies.
    Vulfovich M; Saba N
    Expert Opin Investig Drugs; 2004 Jun; 13(6):577-607. PubMed ID: 15174947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targets in radiotherapy.
    Brown JM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench top to bedside.
    Barinaga M
    Science; 1997 Nov; 278(5340):1036-9. PubMed ID: 9381201
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel targeted radiosensitisers in cancer treatment.
    Zaidi SH; Huddart RA; Harrington KJ
    Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.
    Tortora G; Ciardiello F
    Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.